|
123
|
358
|
4qtdA |
Structure of human jnk1 in complex with sch772984 and the amppnp-hydrolysed triphosphate revealing the second type-i binding mode |
|
108
|
345
|
4qp4A |
Crystal structure of erk2 in complex with n-cyclohexyl-9h-purin-6-amine |
|
110
|
345
|
4qp9A |
Crystal structure of erk2 in complex with 7-(1-propyl-1h-pyrazol-4-yl)-2-(pyridin-4-yl)-5h-pyrrolo[2,3-b]pyrazine |
|
122
|
351
|
4qtbA |
Structure of human erk1 in complex with sch772984 revealing a novel inhibitor-induced binding pocket |
|
105
|
346
|
4qp8A |
Crystal structure of erk2 in complex with 2-(1h-pyrazol-4-yl)-7-(pyridin-3-yl)-5h-pyrrolo[2,3-b]pyrazine |
|
101
|
349
|
4qp6A |
Crystal structure of erk2 in complex with 5h-pyrrolo[2,3-b]pyrazine |
|
111
|
349
|
4qtaA |
Structure of human erk2 in complex with sch772984 revealing a novel inhibitor-induced binding pocket |
|
105
|
349
|
4qp3A |
Crystal structure of erk2 in complex with (s)-2-((9h-purin-6-yl)amino)-3-phenylpropan-1-ol |
|
102
|
349
|
4qp2A |
Crystal structure of erks in complex with 5-chlorobenzo[d]oxazol-2-amine |
|
115
|
349
|
4r3cA |
Crystal structure of p38 alpha map kinase in complex with a novel isoform selective drug candidate |
|
91
|
346
|
4qpaA |
Crystal structure of erk2 in complex with 7-(1-benzyl-1h-pyrazol-4-yl)-2-(pyridin-4-yl)-5h-pyrrolo[2,3-b]pyrazine |
|
103
|
349
|
4n4sA |
A double mutant rat erk2 in complex with a pyrazolo[3,4-d]pyrimidine inhibitor |
|
105
|
345
|
4o6eA |
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of erk2 |
|
106
|
352
|
4n0sA |
Complex of erk2 with caffeic acid |
|
113
|
352
|
4nifB |
Heterodimeric structure of erk2 and rsk1 |
|
97
|
337
|
4mygA |
Mapk13, active form |
|
114
|
351
|
4lopA |
Structural basis of autoactivation of p38 alpha induced by tab1 (tetragonal crystal form) |
|
111
|
349
|
4looA |
Structural basis of autoactivation of p38 alpha induced by tab1 (monoclinic crystal form) |
|
108
|
352
|
4loqA |
Structural basis of autoactivation of p38 alpha induced by tab1 (tetragonal crystal form with bound sulphate) |
|
111
|
348
|
4l8mA |
Human p38 map kinase in complex with a dibenzoxepinone |
|
87
|
348
|
4kipA |
Crystal structure of mitogen-activated protein kinase 14 (p38-h5) complex with 2-(2-chlorophenyl)-n-(5-(cyclopropylcarbamoyl)-2-methylphenyl)-1,3-thiazole-5-carboxamide |
|
105
|
356
|
4kkgA |
Crystal structure of apo and amp-bound jnk3 |
|
111
|
367
|
4l7fA |
Co-crystal structure of jnk1 and ax13587 |
|
114
|
356
|
4kkhA |
The crystal structure of inhibitor-bound jnk3 |
|
102
|
351
|
4ka3A |
Structure of map kinase in complex with a docking peptide |
|
106
|
348
|
4kinA |
Crystal structure of mitogen-activated protein kinase 14 (p38-h5) complex with 5-(2-chlorophenyl)-n-(5-(cyclopropylcarbamoyl)-2-methylphenyl)-2-thiophenecarboxamide |
|
110
|
349
|
4kiqA |
Crystal structure of mitogen-activated protein kinase 14 (p38-h5) complex with ethyl 6-((5-(cyclopropylcarbamoyl)-2-methylphenyl)carbamoyl)-1h-indole-1-carboxylate |
|
107
|
356
|
4kkeA |
The crystal structure of amp-bound jnk3 |
|
100
|
355
|
4ic7A |
Crystal structure of the erk5 kinase domain in complex with an mkk5 binding fragment |
|
105
|
347
|
4iz5A |
Structure of the complex between erk2 phosphomimetic mutant and pea-15 |
|
97
|
354
|
4hyuA |
Crystal structure of jnk1 in complex with jip1 peptide and 4-{4-[4-(3-methanesulfonyl-propoxy)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexan |
|
95
|
354
|
4izyA |
Crystal structure of jnk1 in complex with jip1 peptide and 4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexan |
|
101
|
348
|
4i5hA |
Crystal structure of a double mutant rat erk2 complexed with a type ii quinazoline inhibitor |
|
95
|
354
|
4hysA |
Crystal structure of jnk1 in complex with jip1 peptide and 4-(4-indazol-1-yl-pyrimidin-2-ylamino)-cyclohexan |
|
116
|
348
|
4izaA |
Structure of dually phosphorylated erk2 bound to the pea-15 death effector domain |
|
115
|
350
|
4iz7A |
Structure of non-phosphorylated erk2 bound to the pea-15 death effector domain |
|
68
|
351
|
4ic8A |
Crystal structure of the apo erk5 kinase domain |
|
105
|
356
|
4h36A |
Crystal structure of jnk3 in complex with atf2 peptide |
|
100
|
349
|
4h3pA |
Crystal structure of human erk2 complexed with a mapk docking peptide |
|
104
|
352
|
4h3qA |
Crystal structure of human erk2 complexed with a mapk docking peptide |
|
115
|
356
|
4h3bA |
Crystal structure of jnk3 in complex with sab peptide |
|
105
|
356
|
4h39A |
Crystal structure of jnk3 in complex with jip1 peptide |
|
106
|
348
|
4gt3A |
Atp-bound form of the erk2 kinase |
|
112
|
346
|
4gvaA |
Adp-bound form of the erk2 kinase |
|
111
|
348
|
4gsbA |
Monoclinic crystal form of the apo-erk2 |
|
106
|
347
|
4g6oA |
Crystal structure of the erk2 |
|
109
|
348
|
4g6nA |
Crystal structure of the erk2 |
|
109
|
347
|
4geoA |
P38a map kinase def-pocket penta mutant (m194a, l195a, h228a, i229a, y258a) |
|
103
|
348
|
4fv0A |
Crystal structure of the erk2 complexed with ek3 |
|
105
|
347
|
4fv3A |
Crystal structure of the erk2 complexed with ek6 |
